信达生物(01801.HK)称继续聚焦创新药物研发 料生物医药行业动力持续
信达生物(01801.HK)首席财务官奚浩在亚洲金融论坛上表示,公司目前有23个研发药品进入临床,包括治疗免疫力问题及癌症等多个类别,并有4个药品准备推出市场,未来会继续聚焦於创新药物研发。
他指,生物医药行业过去二十多年来一直在发展,近十年开始有爆发性增长,而港交所(00388.HK)容许未录盈利的生物制药公司在港上市,引起了投资者对行业的投资热情,亚洲区内用於相关研发的资金亦较过去数年倍增,相信行业的动力在今年仍会持续。
奚浩又称,新型冠状病毒疫情显示出全球医疗系统的弱点,即使是最发达的国家亦受到疫情影响,是次经验令市场知道要将焦点放於大众医疗,而集团亦致力於研发一般人买得起的高质素药品,未来会继续投放在研发,进一步国际化及进行更多合作,令产品可接触到更多病人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.